Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-25-010146
Filing Date
2025-03-13
Accepted
2025-03-13 09:30:23
Documents
83
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 2573367
2 ex19.htm EX-19 99895
3 ex21-1.htm EX-21.1 1542
4 ex23-1.htm EX-23.1 3442
5 ex31-1.htm EX-31.1 14038
6 ex31-2.htm EX-31.2 13963
7 ex32-1.htm EX-32.1 4302
8 ex32-2.htm EX-32.2 4272
9 image_001.jpg GRAPHIC 59951
  Complete submission text file 0001493152-25-010146.txt   9903379

Data Files

Seq Description Document Type Size
10 XBRL SCHEMA FILE lpcn-20241231.xsd EX-101.SCH 47631
11 XBRL CALCULATION FILE lpcn-20241231_cal.xml EX-101.CAL 65280
12 XBRL DEFINITION FILE lpcn-20241231_def.xml EX-101.DEF 201049
13 XBRL LABEL FILE lpcn-20241231_lab.xml EX-101.LAB 463231
14 XBRL PRESENTATION FILE lpcn-20241231_pre.xml EX-101.PRE 368794
86 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 1742731
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

IRS No.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-36357 | Film No.: 25734056
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)